Changes in Beneficial Ownership · 4
X4 Pharmaceuticals, Inc.
XFORNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1791230611.xml
Filing details
- Report period
- 2026-10-01
- Issuer
- X4 Pharmaceuticals, Inc
- Issuer CIK
- 0001501697
- Trading symbol
- XFOR
Reporting owner 1
- Name
- KIRSKE DAVID
- Reporting owner CIK
- 0001276750
- Relationship
- Officer
- Officer title
- Chief Financial Officer
- Address
- C/O X4 PHARMACEUTICALS INC., 61 N BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-01 | S · Form 4[F1] | 11,767 | D | 2.8604[F2] | 155,983[F3] | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.↩ 1
- F2
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.82 to $2.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
- F3
- Of the shares of common stock reported, 64,418 shares represent restricted stock units.↩ 1
Signature 1
- Signed
- /s/ Mitch Buckley, attorney-in-fact
- Date
- 2026-10-05
Company context
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain
Current securities
Recent company filings
- Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Regulation FD DisclosureOct 8, 2026
- SCHEDULE 13G/A - filed by FMR LLC regarding X4 Pharmaceuticals, IncOct 7, 2026
- 144 filingOct 1, 2026
- Other EventsSep 9, 2026
- Other EventsSep 8, 2026